<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2019-15-5-736-741</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2045</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>POINT OF VIEW</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ТОЧКА ЗРЕНИЯ</subject></subj-group></article-categories><title-group><article-title>Modern Principles of Treatment of Uncontrolled Hypertension</article-title><trans-title-group xml:lang="ru"><trans-title>Современные принципы лечения неконтролируемой артериальной гипертензии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подзолков</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Podzolkov</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, зав. кафедрой факультетской терапии №2,</p><p>119991, Москва, ул. Трубецкая, 8 стр. 2</p></bio><bio xml:lang="en"><p>MD, PhD, Professor, Head of Chair of Faculty Therapy №2;</p><p>Director of Therapeutic Clinic of University Clinical Hospital №4, </p><p>Trubetskaya ul. 8-2, Moscow, 119991 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарзиманова</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarzimanova</surname><given-names>A. I</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, кафедра факультетской терапии №2, </p><p>119991, Москва, ул. Трубецкая, 8 стр. 2</p></bio><bio xml:lang="en"><p>MD, PhD, Professor, Chair of Faculty Therapy №2,</p><p>Trubetskaya ul. 8-2, Moscow, 119991 </p></bio><email xlink:type="simple">tarzimanova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Георгадзе</surname><given-names>З. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Georgadze</surname><given-names>Z. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., доцент, кафедра факультетской терапии №2, </p><p>119991, Москва, ул. Трубецкая, 8 стр. 2</p></bio><bio xml:lang="en"><p>MD, PhD, Associate Professor, Chair of Faculty Therapy №2,</p><p>Trubetskaya ul. 8-2, Moscow, 119991 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>06</day><month>11</month><year>2019</year></pub-date><volume>15</volume><issue>5</issue><fpage>736</fpage><lpage>741</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Podzolkov V.I., Tarzimanova A.I., Georgadze Z.O., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Подзолков В.И., Тарзиманова А.И., Георгадзе З.О.</copyright-holder><copyright-holder xml:lang="en">Podzolkov V.I., Tarzimanova A.I., Georgadze Z.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2045">https://www.rpcardio.online/jour/article/view/2045</self-uri><abstract><p>Despite the current possibilities of using different classes of antihypertensive drugs that effectively reduce blood pressure and significantly improve the long-term prognosis of patients, the problem of uncontrolled arterial hypertension has not lost its importance and its solution in a particular clinical situation often remains very difficult. The term "uncontrolled arterial hypertension" can be used in all cases where arterial pressure has not been achieved. The true prevalence of uncontrolled arterial hypertension has not been established, and its study is hampered primarily by the fact that not all patients initially receive antihypertensive therapy that meets generally accepted standards. Currently, the tactics of management of patients with uncontrolled hypertension involves the use of combinations of antihypertensive drugs. Rational combinations, according to the new recommendations for the diagnosis and treatment of arterial hypertension in 2018, remain a combination of blockers of the renin-angiotensin-aldosterone system – angiotensin-converting enzyme inhibitors or receptor blockers to angiotensin with a calcium antagonist or diuretic, preferably in one tablet. With the ineffectiveness of dual therapy needs to be assigned to a third antihypertensive drug. Among the most modern antihypertensive drugs can be considered a triple fixed combination of lisinopril, amlodipine and indapamide. All the components included in the composition of the drug, has proved its high efficiency and safety. Uncontrolled arterial hypertension remains one of the most urgent problems of modern cardiology. Many aspects of it are far from unambiguously interpreted solutions and standards. Until the end, the mechanisms of the formation of uncontrolled course of hypertension remain unexplored, which, in turn, leads to a restriction of the use of drug and non-drug methods in the treatment of this pathology. Rational choice of antihypertensive therapy regimens can significantly improve the quality of treatment of this category of patients.</p></abstract><trans-abstract xml:lang="ru"><p>Несмотря на существующие в настоящее время возможности применения различных классов антигипертензивных препаратов, эффективно снижающих артериальное давление (АД) и существенно улучшающих долгосрочный прогноз пациентов, проблема неконтролируемой артериальной гипертензии (АГ) не утратила своего значения, и решение ее в конкретной клинической ситуации зачастую остается весьма сложным. Термин «неконтролируемая АГ» может быть применен во всех случаях, когда целевое АД не достигнуто. Истинная распространенность неконтролируемой АГ не установлена, и изучение ее затруднено в первую очередь тем, что далеко не все пациенты исходно получают антигипертензивную терапию, соответствующую общепринятым стандартам. В настоящее время тактика ведения больных с неконтролируемой АГ предполагает применение комбинаций антигипертензивных препаратов. Рациональными комбинациями, согласно новым рекомендациям по диагностике и лечению АГ (2018 г.), остаются сочетания блокаторов ренин-ангиотензин-альдостероновой системы – ингибиторы ангиотензинпревращающего фермента или блокаторы рецепторов к ангиотензину с антагонистом кальция или диуретиком, предпочтительно, в одной таблетке. При неэффективности двойной терапии должен быть назначен третий антигипертензивный препарат. Среди наиболее современных антигипертензивных препаратов можно считать тройную фиксированную комбинацию лизиноприла, амлодипина и индапамида. Все компоненты, входящие в состав препарата, доказали свою высокую эффективность и безопасность. Неконтролируемая АГ остается одной из наиболее актуальных проблем современной кардиологии. Многие аспекты ее пока далеки от однозначно интерпретируемых решений и стандартов. До конца остаются не изученными механизмы формирования неконтролируемого течения артериальной гипертензии, что, в свою очередь, обусловливает ограничение применения медикаментозных и немедикаментозных методов в лечении даннойпатологии. Рациональный выбор схем антигипертензивной терапии позволяет существенно повышать качество лечения этой категории больных.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>комбинированная терапия</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertension</kwd><kwd>combination therapy</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021-104. DOI:10.1093/eurheartj/ehy339.</mixed-citation><mixed-citation xml:lang="en">2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021-104. DOI:10.1093/eurheartj/ehy339.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Боиц̆ов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная Терапия и Профилактика. 2014;4:4-14. DOI:10.15829/1728-8800-2014-4-4-14.</mixed-citation><mixed-citation xml:lang="en">Boytsov S.A., Balanova Y.A., Shalnova S.A., et al. Arterial hypertension among individuals of 25-64 years old prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14 (In Russ.) DOI:10.15829/1728-8800-2014-4-4-14.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e426-e483. DOI:10.1161/CIR.0000000000000597.</mixed-citation><mixed-citation xml:lang="en">Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e426-e483. DOI:10.1161/CIR.0000000000000597.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Аксенова А.В., Есаулова Т.Е., Сивакова О.А., Чазова И.Е. Резистентная и рефрактерная артериальные гипертонии: сходства и различия, новые подходы к диагностике и лечению. Системные Гипертензии. 2018;15(3):11-3. DOI:10.26442/2075-082X_2018.3.11-13.</mixed-citation><mixed-citation xml:lang="en">Aksenova A.V., Esaulova T.E., Sivakova O.A., Chazova I.E. Resistant and refractory arterial hypertension: similarities and differences, new approaches to diagnosis and treatment. Systemic Hypertension. 2018;15(3):11-3 (In Russ.) DOI:10.26442/2075-082X_2018.3.11-13.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Жернакова Ю.В. Рекомендации по диагностике и лечению артериальнойгипертонии 2018 г.: слово за европейскими экспертами. Системные Гипертензии. 2018;15(3):6-10]. DOI:10.26442/2075-082X_2018.3.6-10.</mixed-citation><mixed-citation xml:lang="en">Chazova I.E., Zhernakova Y.V. Guidelines for diagnostics and treatment of hypertension 2018: European experts’ opinion. Systemic Hypertension. 2018;15(3):6-10 (In Russ.). DOI:10.26442/2075-082X_2018.3.6-10.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Semple P.F., Cumming A.M., Meredith P.A., et al. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man. Cardiovasc Drugs Ther. 1987;1(1):45-50. DOI:10.1007/bf02125832.</mixed-citation><mixed-citation xml:lang="en">Semple P.F., Cumming A.M., Meredith P.A., et al. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man. Cardiovasc Drugs Ther. 1987;1(1):45-50. DOI:10.1007/bf02125832.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Davis B.R., Culter J.A., Gordon D.J. Antihypertensive and lipid-lowering treatment to prevent heart attack trial. Am J Hypertens.1996;9:342-60. DOI:10.1016/0895-7061(96)00037-4.</mixed-citation><mixed-citation xml:lang="en">Davis B.R., Culter J.A., Gordon D.J. Antihypertensive and lipid-lowering treatment to prevent heart attack trial. Am J Hypertens.1996;9:342-60. DOI:10.1016/0895-7061(96)00037-4.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Malacco E., Santonastaso M., Vari N.A., et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther. 2004;26(6):855-65. DOI:10.1016/S0149-2918(04)90129-4.</mixed-citation><mixed-citation xml:lang="en">Malacco E., Santonastaso M., Vari N.A., et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther. 2004;26(6):855-65. DOI:10.1016/S0149-2918(04)90129-4.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Подзолков В.И., Тарзиманова А.И. Значение лизиноприла в клинической практике. Рациональная Фармакотерапия в Кардиологии. 2010;6(4):565- 8. DOI:10.20996/1819-6446-2010-6-4-21-25.</mixed-citation><mixed-citation xml:lang="en">Podzolkov V.I., Tarzimanova A.I. Lisinopril implication in the clinical practice. Rational Pharmacotherapy in Cardiology. 2010;6(4):565-8 (In Russ.) DOI:10.20996/1819-6446-2010-6-4-21-25.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Reisin E., Weir M.R., Falkner B., et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in obese Patients with Hypertension (TROPHY) Study Group. Hypertension. 1997; 30(1 Pt 1):140-5. DOI:10.1161/01.hyp.30.1.140.</mixed-citation><mixed-citation xml:lang="en">Reisin E., Weir M.R., Falkner B., et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in obese Patients with Hypertension (TROPHY) Study Group. Hypertension. 1997; 30(1 Pt 1):140-5. DOI:10.1161/01.hyp.30.1.140.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G., Zanchetti A., Agabiti-Rosei E., et al. Study on monitoring of blood pressure and lisinopril evaluation. Circulation. 1997;95(6);1464-70. DOI:10.1161/01.cir.95.6.1464.</mixed-citation><mixed-citation xml:lang="en">Mancia G., Zanchetti A., Agabiti-Rosei E., et al. Study on monitoring of blood pressure and lisinopril evaluation. Circulation. 1997;95(6);1464-70. DOI:10.1161/01.cir.95.6.1464.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Terpstra W.F., May J.F., Smit A.J., et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19(2):303-9. DOI:10.1097/00004872-200102000-00018.</mixed-citation><mixed-citation xml:lang="en">Terpstra W.F., May J.F., Smit A.J., et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19(2):303-9. DOI:10.1097/00004872-200102000-00018.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mogensen C.E., Neldam S., Tikkanen I., et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274): 1440-4. DOI:10.1136/bmj.321.7274.1440.</mixed-citation><mixed-citation xml:lang="en">Mogensen C.E., Neldam S., Tikkanen I., et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274): 1440-4. DOI:10.1136/bmj.321.7274.1440.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997;349(9068):1787-92. DOI: 10.1016/S0140-6736(96)10244-0.</mixed-citation><mixed-citation xml:lang="en">Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997;349(9068):1787-92. DOI: 10.1016/S0140-6736(96)10244-0.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Roush G.C., Kaur R., Emst M.E. Diuretics: a review and update. J Cardiovasc Phamracol Ther. 2014;19(1):5-13. DOI:10.1177/10742 48413497257.</mixed-citation><mixed-citation xml:lang="en">Roush G.C., Kaur R., Emst M.E. Diuretics: a review and update. J Cardiovasc Phamracol Ther. 2014;19(1):5-13. DOI:10.1177/10742 48413497257.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Roush G.C., Abdelfahah R., Song S., et al. Hydrochlorotiazide and alternative diuretics versus reninangiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head metaanalysis. J Hypertens. 2018;36(6):1247-55. DOI:10.1097/HJH.0000000000001691.</mixed-citation><mixed-citation xml:lang="en">Roush G.C., Abdelfahah R., Song S., et al. Hydrochlorotiazide and alternative diuretics versus reninangiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head metaanalysis. J Hypertens. 2018;36(6):1247-55. DOI:10.1097/HJH.0000000000001691.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Подзолков В.И., Драгомирецкая Н.А. Применение фиксированной комбинации лизиноприла и индапамида для кардиопротекции у больных гипертонической болезнью. Артериальная Гипертензия. 2018;24(4):459-68. DOI:10.18705/1607-419Х-2018-24-4-459-468.</mixed-citation><mixed-citation xml:lang="en">Podzolkov V.I., Dragomiretskaya N.A. The fixed combination of lisinopril and indapamide: optimization of cardio protection in hypertensive patients. Arterial Hypertension. 2018;24(4):459-68 (In Russ.) DOI:10.18705/1607-419Х-2018-24-4-459-468.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kaplan N.M. Indapamide: is it the better diuretic for hypertension? Hypertension. 2015;65(5):983- 984. DOI:10.1161/HWERTENSIONAHA.115.05138.</mixed-citation><mixed-citation xml:lang="en">Kaplan N.M. Indapamide: is it the better diuretic for hypertension? Hypertension. 2015;65(5):983- 984. DOI:10.1161/HWERTENSIONAHA.115.05138.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Musini V.M. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;(5):CD003824. DOI:10.1002/14651858. CD003824.pub2.</mixed-citation><mixed-citation xml:lang="en">Musini V.M. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;(5):CD003824. DOI:10.1002/14651858. CD003824.pub2.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Olde Engberink R.H., Frenkel W.J., van den Bogaard B., et al. Effects of thiazide-type and thiazidelike diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension.2015;65(5):1033-40. DOI:10.1161/HYPERTENSIONAHA.114.052.</mixed-citation><mixed-citation xml:lang="en">Olde Engberink R.H., Frenkel W.J., van den Bogaard B., et al. Effects of thiazide-type and thiazidelike diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension.2015;65(5):1033-40. DOI:10.1161/HYPERTENSIONAHA.114.052.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Liang W., Ma H., Cao L., et al. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a metaanalysis. J Cell Mol Med.2017;21(11):2634-42. DOI:10.1111/jcmm.13205.</mixed-citation><mixed-citation xml:lang="en">Liang W., Ma H., Cao L., et al. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a metaanalysis. J Cell Mol Med.2017;21(11):2634-42. DOI:10.1111/jcmm.13205.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция по медицинскому применению препарата Диротон® Плюс. [цитировано 10.09.2019]. Доступно на: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d57c9ce3-239c-47f1-9d97-195471241054&amp;t=.</mixed-citation><mixed-citation xml:lang="en">Instructions for medical use of the drug Diroton® Plus. [cited by Sep 10, 2019]. Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d57c9ce3-239c-47f1-9d97-195471241054&amp;t= (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Карпов Ю.А. Тройная комбинация антигипертензивных и липидснижающих препаратов – эффективное снижение риска сердечно-сосудистых осложнений у пациентов c артериальной гипертонией. Русский Медицинский Журнал. 2015;27:1580-3.</mixed-citation><mixed-citation xml:lang="en">Karpov Y. А. Triple combination of antihypertensive and lipid-lowering drugs is an effective reduction of the risk of cardiovascular complications in patients with arterial hypertension. Russian Medical Journal. 2015;27:1580-3 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Pall D., Katona E., Juhasz M., et al. Prevention of target organ damage with modern antihypertensive agents. Orv Hetil. 2006;147(32):1505-11.</mixed-citation><mixed-citation xml:lang="en">Pall D., Katona E., Juhasz M., et al. Prevention of target organ damage with modern antihypertensive agents. Orv Hetil. 2006;147(32):1505-11.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hernández R.H., Armas-Hernández M.J., Velasco M. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther. 2003;10(6):409-14.</mixed-citation><mixed-citation xml:lang="en">Hernández R.H., Armas-Hernández M.J., Velasco M. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther. 2003;10(6):409-14.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jоrgensen B., Thaulow E. Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study. Am Heart J. 2003;145(6):1030-5. DOI:10.1016/S0002-8703 (03)00082-6.</mixed-citation><mixed-citation xml:lang="en">Jоrgensen B., Thaulow E. Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study. Am Heart J. 2003;145(6):1030-5. DOI:10.1016/S0002-8703 (03)00082-6.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Nissen S.E., Tuzcu E.M., Libby P., et al.; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-25. DOI:10.1001/jama. 292.18.2217.</mixed-citation><mixed-citation xml:lang="en">Nissen S.E., Tuzcu E.M., Libby P., et al.; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-25. DOI:10.1001/jama. 292.18.2217.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">McCarty M.F. Concurrent treatment with an ACE inhibitor may amplify the utility of calcium supplementation for control of hypertension. Med Hypotheses. 2004;63(5):818-22. DOI:10.1016/j.mehy.2002.11.001.</mixed-citation><mixed-citation xml:lang="en">McCarty M.F. Concurrent treatment with an ACE inhibitor may amplify the utility of calcium supplementation for control of hypertension. Med Hypotheses. 2004;63(5):818-22. DOI:10.1016/j.mehy.2002.11.001.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
